Clik here to view.
Fujifilm Completes Acquisition of Irvine Scientific Sales Company and IS...
SANTA ANA, Calif. FUJIFILM Corporation (President: Kenji Sukeno) announced today that it has completed the acquisition of Irvine Scientific Sales Company, Inc. (ISUS) and IS JAPAN CO.,LTD. (ISJ),...
View ArticleClik here to view.
Takeda and TiGenix Announce Results of First Acceptance Period for the...
OSAKA, Japan & LEUVEN, Belgium Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and Nasdaq: TIG) (“TiGenix”) today announced the results of the...
View ArticleClik here to view.
サンバイオ：再生細胞薬「SB623」の開発進捗総括の更新について
東京 （ビジネスワイヤ） — 平成30年３月13日付リリース『再生細胞薬「SB623」の開発進捗総括の更新について』に記載した「SB623」の開発の進捗に動きがあり、これに伴い一部の内容を更新しました。更新箇所は下線の部分であります。 記...
View ArticleClik here to view.
SanBio: Update on Development Progress of Regenerative Cell Medicine SB623
TOKYO The SanBio Group (SanBio Co., Ltd. and subsidiary SanBio Inc.) (TOKYO:4592) has updated part of its March 13, 2018 release “Update on Development Progress of Regenerative Cell Medicine SB623”....
View ArticleClik here to view.
AVITA Medical RECELL® Device Pivotal Trial Results in Second-Degree Burns...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, OTCQX: AVMXY) announced today that results from a pivotal clinical trial demonstrating the effectiveness and clinical benefits of...
View ArticleClik here to view.
AVITA Medical Announces Acquisition of Manufacturing Facility to Support...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced that it has entered into an agreement to acquire a manufacturing facility to support the planned...
View ArticleClik here to view.
Takeda and TiGenix Announce Results of Second Acceptance Period for the...
OSAKA, Japan & LEUVEN, Belgium Takeda Pharmaceutical Company Limited (TSE: 4502): This press release features multimedia. View the full release here:...
View ArticleClik here to view.
AVITA Medical Announces Expansion of Management Team to Support Planned U.S....
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH) (OTCQX: AVMXY) today announced that it expanded its management team in the commercial, legal and medical affairs functions to...
View ArticleClik here to view.
SanBio: Joint Research Agreement for SB623 Targeting Dementia
TOKYO SanBio Company Limited, a scientific leader in regenerative medicine for neurological disorders, today announced it has concluded an agreement with Keio University School of Medicine on joint...
View ArticleClik here to view.
SanBio: Acquisition of a Patent Portfolio Regarding Cell Medicines Derived...
TOKYO The SanBio Group, a scientific leader in regenerative medicine for neurological disorders, today announced the acquisition of a patent portfolio regarding cell medicines derived from...
View ArticleClik here to view.
AVITA Medical Announces FDA Approval of the RECELL® System for the Treatment...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH) (OTCQX: AVMXY), a global regenerative medicine company, today announced that the U.S. Food and Drug Administration (FDA) approved...
View ArticleClik here to view.
SanBio: Supplementary Information to the Notice Regarding an Equity and...
TOKYO SanBio Co., Ltd. (representative: Keita Mori, headquarters: Chuo-ku, Tokyo; hereinafter SanBio) has agreed to enter into an equity and business alliance with CareNet, Inc. (representative:...
View ArticleClik here to view.
SanBio: Notice Regarding an Equity and Business Alliance Between Five...
TOKYO SanBio Co., Ltd. (representative: Keita Mori, headquarters: Chuo-ku, Tokyo; hereinafter SanBio) hereby announces that it has resolved to enter into an equity and business alliance (hereinafter...
View ArticleClik here to view.
ＰＨＣホールディングス株式会社：細胞治療・再生医療分野を中心としたヘルスケアソリューションの開発強化のために、新たな首都圏研究開発拠点を設置
東京 （ビジネスワイヤ） — ＰＨＣホールディングス株式会社（本社：東京都港区）の１００％子会社である、ＰＨＣ株式会社（以下、「ＰＨＣ」）は、このたび、湘南ヘルスイノベーションパーク（*１）（以下、「湘南アイパーク」）における研究開発活動を開始しましたので、お知らせいたします。...
View ArticleClik here to view.
Notice of Personnel Changes to Corporate Officers at SanBio Co., Ltd. and at...
TOKYO SanBio Co., Ltd. and US subsidiary SanBio, Inc. conducted the following personnel transfers, effective October 1, 2018. 1. Transfer DetailsAkihiro Tsujimura will become a senior corporate...
View ArticleClik here to view.
Clik here to view.
PharmAbcine宣布FDA受理TTAC-0001用于治疗复发胶质母细胞瘤的IND申请
韩国大田 (美国商业资讯) — PharmAbcine, Inc是一家临床阶段生物技术公司，开发新型抗体治疗药物，用于多种癌症适应证，该公司宣布已收到美国食品药品管理局(FDA)针对其旗舰抗体TTAC-0001在研新药(“IND”)申请而签发的“可开展研究通知书”。该通知书允许公司开始启动美国临床试验单位开展贝伐珠单抗(Avastin®)难治复发GBM患者II期临床试验。...
View ArticleClik here to view.
WellSky and Digi-Trax Partner to Power Safer and More Efficient Cellular...
LENEXA, Kan. WellSky, a leading health and community care technology company backed by TPG Capital, and Digi-Trax Corporation, a global leader in compliance labeling solutions, have formed an...
View ArticleClik here to view.
德累斯顿心脏中心成为Imricor的首家商业化临床单位
明尼阿波利斯 (美国商业资讯) — Imricor今天宣布，该公司与德国德累斯顿心脏中心签署Advantage-MR EP记录仪/刺激仪系统并支持Vision-MR器械1的首份商业化合同。该协议将德累斯顿心脏中心置于MRI引导心脏消融临床进展的前沿，使该医院成为成长中的介入心脏磁共振(iCMR)领域的全球领导者。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
James Till教授因干细胞发现而荣获2018年度江户川Niche奖
东京 (美国商业资讯) — 江户川Niche奖(The Edogawa Niche Prize)由日印再生医学中心(NCRM)与日本东京江户川病院联合设立，2018年度该奖项授予加拿大多伦多大学名誉教授James Till，以表彰他在20世纪60年代与Ernest McCulloch教授合作发现了干细胞(www.edogawanicheprize.org)。...
View Article